[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Antibody Pipeline Database: 1-Year Subscription

November 2010 | | ID: AACB4B3C13FEN
La Merie Publishing

US$ 1,638.00

Online Subscription

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Subscription to La Merie’s proprietary Antibody Pipeline Database provides online access to more than 1,600 project entries for therapeutic antibodies on the market and in research & development. Each project is specified for its Target or Mechanism of Action, Therapeutic Area and R&D Phase. Use of the R&D database of therapeutic antibodies is intuitive. Data sets of interest can be printed and exported. Projects are being updated continuously. The R&D history of each project with online references of information sources can be viewed and printed. Sales figures of major products are provided. The projects can be segmented into Territories, Therapeutic Areas and R&D Phases. An advanced search function allows to combine search parameters. A scroll down menu for predefined targets conveniently selects projects of interest. By clicking on column heads of the project list, projects can be arranged in ascending or descending alphabetical or numerical order, e.g. for phase, product category or company name. Sample screenshots illustrate the database.

Purchase of the subscription provides a 1-year online access to the data of the Antibody Pipeline Database. Credentials to access the database will be sent by e-mail within 24 hours after purchase.

Benefits from the Antibody Pipeline Database:

New database with no historical burden
Intuitive use
Designed for structured searches
Focused on targets, therapeutic areas and R&D phases
Ideal for competitor analysis (companies, targets, product categories)
Cost-effective and rapid solution for benchmarking
Identification of licensing candidates

Project listing in a tabular format:

Drug Codes
Target / Mechanism of Action
Class of Compound
Product Category
Company
Territory
Therapeutic Area
Indication
R&D Phase

Therapeutic Areas:

Cardiovascular & blood
Dermatology
Gastrointestinal
Genitourinary, renal & gynecology
Infectious & toxicology
Metabolism & endocrine
Neurology & psychiatry
Oncology
Ophthalmology & otorhinolaryngology
Orthopedics, dental, anesthesia & surgery
Pulmonary & respiratory
Rheumatoid & autoimmune

Predefined Targets of the Scroll Down Menu:

Anti-Infective Antibodies
Antibody-Drug Conjugates (ADC)
Biosimilar & Biobetter/Biosuperior Antibodies
c-MET/HGF Inhibitors
CD3 Antagonists
CD19 Antagonists
CD20 Antibodies
CD22 Antibodies
CD30 Antibodies
CD40/L
CEA Antibodies
Death Receptors TRAIL-R1/2
EGF-R Agonists and Antagonists
EpCAM Antagonists
GM-CSF Antibodies
Her2 Antagonists
IGF-1R Antagonists
Immunocytokines
Immunotoxins
Interleukin-1/R Antagonists
Interleukin-6/R Antagonists
Interleukin-12/23 Antagonists
Interleukin-13 Antagonists
Interleukin-17 Antagonists
Integrin Antagonists
NGF Antagonists
PDGF-R Agonists and Antagonists
TGF-R Agonists and Antagonists
TNF Antagonists
TRAIL-R1/R2 (Death Receptors)
VEGF and VEGF-R Agonists and Antagonists


More Publications